title: Outcome of Asunaprevir/Daclatasvir Combination Therapy for Chronic Liver Disease Type C.
abstract: OBJECTIVE
  Treatment for chronic hepatitis C has recently developed in a very rapid manner. In Japan, in September 2014, IFN-free asunaprevir (ASV) and daclatasvir (DCV) became available for combination therapy. We report the treatment outcomes achieved at our hospital using this combination therapy.
  
  
  METHODS
  Sustained virological response (SVR) 24 could be evaluated in 120 of 125 patients with chronic liver disease type C who visited our hospital and were treated with ASV/DCV after September 2014, and these patients were analyzed.
  
  
  RESULTS
  SVR24 was achieved in 106 patients (88%). End-of-treatment response was not achieved in 10 patients (8.3%). Five of them carried multiple-resistant NS3/4A or NS5A region, and administration was discontinued early in 4 patients due to adverse effects. After ASV/DCV treatment, hepatocellular carcinoma (HCC) developed in 2 patients (1.7%) and recurred in 5 (4.2%).
  
  
  CONCLUSIONS
  ASV/DCV treatment achieved favorable SVR in elderly and hepatic cirrhosis patients and patients in whom HCC was cured. However, an increase in the incidence of HCC development in patients who markedly respond to direct-acting antivirals treatment is expected and surveillance of HCC becomes more important.
authors.forename: Satoru
authors.initials: S
authors.lastname: Hagiwara
authors.forename: Naoshi
authors.initials: N
authors.lastname: Nishida
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Watanabe
authors.forename: Toshiharu
authors.initials: T
authors.lastname: Sakurai
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Ida
authors.forename: Yasunori
authors.initials: Y
authors.lastname: Minami
authors.forename: Masahiro
authors.initials: M
authors.lastname: Takita
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Minami
authors.forename: Mina
authors.initials: M
authors.lastname: Iwanishi
authors.forename: Hirokazu
authors.initials: H
authors.lastname: Chishina
authors.forename: Kazuomi
authors.initials: K
authors.lastname: Ueshima
authors.forename: Yoriaki
authors.initials: Y
authors.lastname: Komeda
authors.forename: Tadaaki
authors.initials: T
authors.lastname: Arizumi
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Kudo
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002219:Carbamates; D006528:Carcinoma, Hepatocellular / Q000209:etiology; D018432:Drug Resistance, Multiple; D024882:Drug Resistance, Viral; D004359:Drug Therapy, Combination; D005260:Female; D016174:Hepacivirus / Q000187:drug effects; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage* / Q000009:adverse effects; D007546:Isoquinolines / Q000008:administration & dosage* / Q000009:adverse effects; D008103:Liver Cirrhosis / Q000188:drug therapy; D008113:Liver Neoplasms / Q000209:etiology; D008297:Male; D008875:Middle Aged; D011759:Pyrrolidines; D012008:Recurrence; D013449:Sulfonamides / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome; D014633:Valine / Q000031:analogs & derivatives
chemical_list: D000998:Antiviral Agents; D002219:Carbamates; D007093:Imidazoles; D007546:Isoquinolines; D011759:Pyrrolidines; D013449:Sulfonamides; D014633:Valine; C549273:daclatasvir; C571889:asunaprevir